Poster
155
(#155) Clinical Outcomes of Vesicular Monoamine Transporter 2 Inhibitor Versus Non-Vesicular Monoamine Transporter 2 Inhibitor Treatments Among Patients With Tardive Dyskinesia in Long-Term Care
Psych Congress 2025
Abstract: Background: Data on treatment outcomes for tardive dyskinesia (TD) in long-term care (LTC) settings are limited. This study compared clinical outcomes of appropriate TD management using VMAT2 inhibitors versus non-VMAT2 treatments among patients in LTC.
Methods: A retrospective analysis of PointClickCare's database (June 2016-October 2023) included patients aged ≥18 years entering LTC with a TD diagnosis (ICD-10 G24.01, G25.9, or G25.89). Patients were indexed at first VMAT2 or non-VMAT2 prescription post-diagnosis, with ≥6 months of pre-index and ≤12 months of post-index data. VMAT2 users were matched 1:1 with non-VMAT2 users. Outcomes included treatment persistence, falls, emergency department (ED) visits, hospitalizations per patient per year (PPPY, standardized over follow-up period), and changes in activities of daily living (ADL) and Abnormal Involuntary Movement Scale (AIMS) scores.
Results: Among 556 matched patients (278 per group), VMAT2 users had significantly fewer falls (mean [SD] PPPY 2.67 [5.67] vs 4.23 [8.92]; P=.013) and ED visits (0.11 [0.55] vs 0.22 [0.79]; P=.004) than non-VMAT2 users. No statistically significant differences were observed in treatment persistence, number of hospitalizations, and ADL changes from baseline. Only 133 (48%) and 121 (44%) of VMAT2 and non-VMAT2 users, respectively, had a complete AIMS assessment at baseline and follow-up, with no significant difference in total AIMS between treatment groups.
Conclusions: In LTC settings, VMAT2 inhibitor treatment for TD is associated with fewer falls and ED visits. As fall reduction is a key quality measure, treatment with VMAT2 inhibitors may improve this outcome. In addition, standardized assessments like AIMS remain underused.
Short Description: This study among patients in long-term care with tardive dyskinesia (TD) found that those treated with vesicular monoamine transporter 2 (VMAT2) inhibitors experienced significantly fewer falls and emergency department visits compared with patients on non-VMAT2 inhibitors. No differences were seen in hospitalizations or functional scores. The research highlights the benefits of on-label VMAT2 inhibitor treatment and reveals underuse of standardized movement assessments, emphasizing the need for better management of TD in long-term care settings.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
Methods: A retrospective analysis of PointClickCare's database (June 2016-October 2023) included patients aged ≥18 years entering LTC with a TD diagnosis (ICD-10 G24.01, G25.9, or G25.89). Patients were indexed at first VMAT2 or non-VMAT2 prescription post-diagnosis, with ≥6 months of pre-index and ≤12 months of post-index data. VMAT2 users were matched 1:1 with non-VMAT2 users. Outcomes included treatment persistence, falls, emergency department (ED) visits, hospitalizations per patient per year (PPPY, standardized over follow-up period), and changes in activities of daily living (ADL) and Abnormal Involuntary Movement Scale (AIMS) scores.
Results: Among 556 matched patients (278 per group), VMAT2 users had significantly fewer falls (mean [SD] PPPY 2.67 [5.67] vs 4.23 [8.92]; P=.013) and ED visits (0.11 [0.55] vs 0.22 [0.79]; P=.004) than non-VMAT2 users. No statistically significant differences were observed in treatment persistence, number of hospitalizations, and ADL changes from baseline. Only 133 (48%) and 121 (44%) of VMAT2 and non-VMAT2 users, respectively, had a complete AIMS assessment at baseline and follow-up, with no significant difference in total AIMS between treatment groups.
Conclusions: In LTC settings, VMAT2 inhibitor treatment for TD is associated with fewer falls and ED visits. As fall reduction is a key quality measure, treatment with VMAT2 inhibitors may improve this outcome. In addition, standardized assessments like AIMS remain underused.
Short Description: This study among patients in long-term care with tardive dyskinesia (TD) found that those treated with vesicular monoamine transporter 2 (VMAT2) inhibitors experienced significantly fewer falls and emergency department visits compared with patients on non-VMAT2 inhibitors. No differences were seen in hospitalizations or functional scores. The research highlights the benefits of on-label VMAT2 inhibitor treatment and reveals underuse of standardized movement assessments, emphasizing the need for better management of TD in long-term care settings.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
